Tracers / [211At]At-astatinated

[211At]At-astatinated

Also written as [At-211]astatinated; [At-211]Astatinated

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 0

Prostate cancer PSMA-directed radioligand therapy

What it is

Compound class: Glu-urea based PSMA inhibitor (small molecule)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 33601187
Clinical application: Targeted alpha particle therapy of metastatic prostate cancer PMID 33601187
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [211At]At-astatinated, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article).